Gabather aims to improve the treatment of neuropsychiatric disorders by developing drugs aimed at treating a wide range of such disorders.
Its lead candidate, GT-002, is currently undergoing a clinical phase I study with positive preliminary results. The company is now conducting a rights issue in order to intensify business development.
See Gabather’s CEO Michael-Robin Witt present the company, in.